Lysosomal acid glucosylceramidase

BE0000978ProteinHumansGBA1

Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) into free ceramides (such as N-acylsphing-4-enine) and glucose (PubMed:15916907, PubMed:24211208, PubMed:32144204, PubMed:39395789, PubMed:9201993). It is acted on by 10 drugs in DrugBank.

Gene name
GBA1
UniProtKB entry
P04062Swiss-Prot
Cellular location
Lysosome membrane
Residues / weight
536 residues · 59,716 Da
Also known as
3.2.1.45 · Acid beta-glucosidase · Alglucerase · Beta-GC · Beta-glucocerebrosidase

Resolves to

Protein
UniProtP04062UniProt nameGBA1_HUMAN
Gene
HGNCHGNC:4177NCBI Gene2629GenBank183008GeneCardsGBA1
Pharmacology
KEGGhsa:2629
Structure
PDB1OGSPDB1Y7VPDB2F61
Drugs

What you can answer from here — as of September 03, 2024

10DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
14Clinical trialsTrials of drugs acting on it, by phase and status
Sign in
24GO termsFunction, process and component, as structured annotations
Sign in
2Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
96+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Lysosomal acid glucosylceramidase, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In